Genetic variations in the micro-RNA (miRNA) processing pathway genes and miRNA binding sites could predict a woman's risk of developing ovarian cancer and her prospects for survival.
The study by researchers from The University of Texas M. D. Anderson Cancer Center was the first to examine the association of genetic variants related to miRNA with ovarian cancer risk, overall survival for ovarian cancer patients, and platinum-based chemotherapy response.
"We found a gene dosage effect, the more unfavorable variations a woman has, the greater her ovarian cancer risk and the shorter her survival time," said senior author Xifeng Wu, M.D., Ph.D., professor in M. D. Anderson's Department of Epidemiology.
They found that median survival, for example, ranged from 151 months for women with fewest unfavorable variations to 24 months for those with the most.
It was also found that many of the variations indicated likely response to platinum-based chemotherapy.
"Our findings have the potential clinical application of indicating a patient's prognosis and showing who will respond to different therapies by analyzing a single blood sample. We also will incorporate this genetic information with epidemiological information to build a comprehensive model to predict susceptibility to ovarian cancer," said Wu.
Researchers focused on the miRNA-processing pathway because it is crucial to production of miRNAs, the small molecules that regulate between one third and half of all genes.
Also, they chose the binding sites on host genes where miRNAs exert their effects on gene expression.